MannKind Corporation (MNKD)
| Market Cap | 1.10B -21.1% |
| Revenue (ttm) | 360.78M +21.2% |
| Net Income | -23.91M |
| EPS | -0.09 |
| Shares Out | 308.95M |
| PE Ratio | n/a |
| Forward PE | 15.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,013,770 |
| Open | 3.320 |
| Previous Close | 3.560 |
| Day's Range | 3.260 - 3.880 |
| 52-Week Range | 2.230 - 6.510 |
| Beta | 1.04 |
| Analysts | Buy |
| Price Target | 9.22 (+159.72%) |
| Earnings Date | May 6, 2026 |
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in... [Read more]
Financial Performance
In 2025, MannKind's revenue was $348.97 million, an increase of 22.23% compared to the previous year's $285.50 million. Earnings were $5.86 million, a decrease of -78.75%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for MNKD stock is "Buy." The 12-month stock price target is $9.22, which is an increase of 159.72% from the latest price.
News
MannKind price target lowered to $7 from $8 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on MannKind (MNKD) to $7 from $8 and keeps an Outperform rating on the shares.
MannKind price target raised to $10 from $8 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on MannKind (MNKD) to $10 from $8 and keeps a Buy rating on the shares. MannKind’s Q1 results missed estimates but this does
MannKind price target raised to $10 from $8 at Wells Fargo
Wells Fargo raised the firm’s price target on MannKind (MNKD) to $10 from $8 and keeps an Overweight rating on the shares following the disclosure of the company’s involvement with
MannKind reports Q1 EPS (2c), consensus 1c
Reports Q1 revenue $90.17M, consensus $105.31M. “We are making meaningful progress executing our corporate transformation strategy, focused on the expansion and diversification of both our commercial ...
MannKind Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 15% year-over-year to $90M, driven by FUROSCIX and strong underlying demand. Two major regulatory catalysts—Afrezza Pediatrics and FUROSCIX ReadyFlow—are expected to accelerate growth in the second half, with reaffirmed 2026 FUROSCIX revenue guidance of $110M-$120M.
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through inn...
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of rali...
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through ...
MannKind price target lowered to $8 from $10 at Mizuho
Mizuho lowered the firm’s price target on MannKind (MNKD) to $8 from $10 and keeps an Outperform rating on the shares. The firm adjusted estimates and price targets for several
MannKind price target lowered to $6 from $7 at Truist
Truist lowered the firm’s price target on MannKind (MNKD) to $6 from $7 and keeps a Buy rating on the shares as part of a broader research note previewing Q1
Theravance Biopharma price target raised to $17 from $14 at B. Riley
B. Riley raised the firm’s price target on Theravance Biopharma (TBPH) to $17 from $14 and keeps a Neutral rating on the shares. The final generic settlement with Mankind (MNKD)
MannKind Transcript: Barclays 28th Annual Global Healthcare Conference
The organization is rapidly transforming into a diversified commercial entity, expecting double-digit revenue growth and two major product launches this year. Key partnerships, product innovation, and international expansion are driving momentum, with a strong financial position supporting future growth.
MannKind Transcript: Leerink Global Healthcare Conference 2026
Management outlined a strategic shift to diversified, high-growth revenue streams, with FUROSCIX® and Afrezza now surpassing royalty income. Major launches and pipeline milestones are expected in 2024. Cost reductions and productivity gains are anticipated from the auto-injector, while the company targets pediatric and hospital market opportunities.
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured a...
MannKind Announces Settlement of Convertible Senior Notes
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal am...
MannKind price target lowered to $8 from $10 at Wedbush
Wedbush lowered the firm’s price target on MannKind (MNKD) to $8 from $10 and keeps an Outperform rating on the shares. Last week’s Q4 update, despite strong revenue across all
MannKind to Participate in Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
The biotech sector took a hit this week despite a recent spike in search activity. The SPDR S&P Biotech ETF ($XBI) and iShares Biotechnology ETF ($IBB) declined slightly, while two
MannKind price target lowered to $7 from $8 at Wells Fargo
Wells Fargo analyst Tiago Fauth lowered the firm’s price target on MannKind (MNKD) to $7 from $8 and keeps an Overweight rating on the shares. The firm thinks the stock
MannKind price target lowered to $8 from $11 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on MannKind (MNKD) to $8 from $11 and keeps a Buy rating on the shares. The stock is down 45% since the announcement
MannKind downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded MannKind (MNKD) to Sector Perform from Outperform with a price target of $3.50, down from $7.50. The firm believes the company’s Tyvaso DPI royalty outlook will likely
MannKind Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Revenue grew 46% to nearly $350 million in 2025, with projections above $450 million in 2026 driven by pipeline progress and product launches. Key clinical programs, including MNKD-201 for IPF and Afrezza pediatric expansion, are advancing, while FUROSCIX and Tyvaso DPI royalties support long-term growth.
MannKind Earnings Call Transcript: Q4 2025
Record 2025 revenue of $349M was driven by Afrezza and FUROSCIX growth, with strong Q4 results and a diversified portfolio. Upcoming catalysts include Afrezza pediatric and FUROSCIX auto-injector launches, while Tyvaso DPI royalties and a robust pipeline support future growth.
MannKind reports Q4 EPS (5c) vs 3c last year
Reports Q4 revenue $112M vs $76.776M last year. “MannKind (MNKD) closed 2025 with strong momentum across our commercial portfolio and meaningful progress in our pipeline. The addition of Furoscix stre...
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs.